Beta Bionics, Inc. (BBNX) company profile
Close on Nov 17, 2026Market cap $800.28MP/E –Yield –
About Beta Bionics
Surgical & Medical Instruments & Apparatus, SIC 3841
Beta Bionics, Inc. is a medical technology company that develops and commercializes automated insulin delivery solutions for diabetes management. The company's primary commercial offering is the iLet, an automated insulin dosing system, alongside related single-use products and components. Its technology is designed for patients with type 1 diabetes, specifically cleared for adults and children aged six and older. The company distributes its medical devices and supplies to patients through healthcare channels, including durable medical equipment providers and pharmacy benefit plans.
The company conducts its commercial operations in the United States, where its primary device has received regulatory clearance. It maintains business relationships with multiple distributors across domestic channels to distribute its systems and consumable supplies. Beta Bionics is incorporated in Delaware and maintains its principal executive offices and corporate headquarters in Irvine, California.
Summary of the business section of Beta Bionics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Beta Bionics, Inc.
- Headquarters
- Irvine, CA
- Address
- 11 Hughes 92618
- Phone
- (949) 427-7785
- Website
- betabionics.com
- Employees
- 420, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- BBNX
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2025
- Shares outstanding
- 54M, Oct 26, 2026
- Public float
- $632.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1674632
- CUSIP
- 08659B102
- ISIN
- US08659B1026
- FIGI
- BBG00JNGG9Q2
- Share class FIGI
- BBG00JNGG9R1
- EIN
- 47-5386878
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean Saint | President & CEO, Director | 398,429 |
| Stephen Feider | Chief Financial Officer | 159,378 |
| Mark Hopman | Chief Commercial Officer | 54,143 |
| Mike Mensinger | Chief Product Officer | 174,740 |
| Steven Jon Russell | Chief Medical Officer | 207,699 |
| Christy Jones | Director | 19,564 |
| Danny L. Dearen | Director | 32,209 |
| Sean Carney | Director | 32,209 |
| Gerard J. Michel | Director | 33,509 |
| Maria Palasis | Director | 29,397 |
| Adam Lezack | Director | 27,399 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Sean Saint President and Chief Executive Officer | $700.00K | $1.58M | $8.98M | $894.60K | $31.00K | $12.19M | +1277% |
| Stephen Feider Chief Financial Officer | $475.00K | $689.49K | $3.68M | $333.88K | $23.50K | $5.20M | +688% |
| Mike Mensinger Chief Product Officer (5) | $450.00K | $513.45K | $2.34M | $316.31K | $23.25K | $3.64M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 31, 2025
- Offer price
- $17.00
- Securities offered
- 12,000,000
- Gross proceeds
- $204.00M
- Exchange
- Nasdaq
- First trading day
- Jan 30, 2025
- First-day close
- $23.63+39.0%
- Lock-up ends (est.)
- Jul 29, 2025
“Per Share Total Initial public offering price $ 17.00 $ 204,000,000 Underwriting discounts and commissions (1) $ 1.19 $ 14,280,000 Proceeds, before expenses, to Beta Bionics, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 420 full-time employees and three part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 27, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?